DOCSLIB.ORG

[Product Name] 500 Mg + 2 Mg Tablet Paracetamol + Thiocolchicoside

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
[Product Name] 500 Mg + 2 Mg Tablet Paracetamol + Thiocolchicoside Package leaflet: Information for the user [Product name] 500 mg + 2 mg Tablet Paracetamol + Thiocolchicoside This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What [Product name] is and what it is used for 2. What you need to know before you take [Product name] 3. How to take [Product name] 4. Possible side effects 5. How to store [Product name] 6. Contents of the pack and other information 1. What [Product name] is and what it is used for This medicine is a muscle relaxant. It is used in adults and adolescents from 16 years old as an adjunctive treatment for painful muscle contractions. It is used for spine-related acute episodes. 2. What you need to know before you take [Product name] Do not take [Product name]: - if you are allergic to paracetamol, thiocolchicoside or any of the other ingredients of this medicine (listed in section 6). - if you are pregnant, if you may be pregnant or think you may be pregnant; - if you are a woman of childbearing potential who does not use contraceptive methods; - if you are breast-feeding; - if you suffer from severe liver disease; - if you suffer from flaccid paralysis or muscular hypotonia; - if you have a kidney disorder. Warnings and precautions Talk to your doctor or pharmacist before taking [Product name]. Concomitant treatment with drugs that have potentially hepatotoxic action should be avoided. Do not associate with alcoholic beverages intake. 1 Respect strictly the doses and duration of treatment detailed in section 3. You should not use this product at a higher dose or for longer than 7 days. This is because one of the products that forms in your body when taking thiocolchicoside at high doses may cause damage to some cells (abnormal number of chromosomes). This has been proven in animal studies and laboratory studies. In humans, this type of cell damage is a risk factor for cancer, fetal lesions and fertility problems in men. Talk to your doctor if you have further questions. The doctor will tell you about all the measures related to effective contraception and the potential risk of a pregnancy. If you notice any symptoms that may indicate liver damage during treatment with [Product name] (e.g. loss of appetite, nausea, vomiting, abdominal discomfort, fatigue, dark urine, jaundice, pruritus), you should stop taking [Product name] and seek immediate medical advice. You should tell your doctor if you experience any of the following symptoms: Convulsion. Children and adolescents Do not give this medicine to children and adolescents under 16 years of age due to safety concerns. Other medicines and [Product name] Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. [Product name] may increase the toxicity of chloramphenicol. [Product name] may potentiate the effect of anticoagulants. The simultaneous administration of [Product name] with aspirin, salicylates or non-steroidal anti- inflammatory drugs is not recommended. Simultaneous use of diflunisal with [Product name] increases the risk of hepatotoxicity. The expected analgesic response of this drug is altered by the administration of barbiturates. The effect of [Product name] is inhibited by the administration of colestipol, cholestyramine and estrogens. Isoniazid enhances the hepatotoxic capacity of [Product name]. [Product name] may cause increase in the following laboratory values: transaminases, alkaline phosphatase, ammonia, creatinine, lactate dehydrogenase and urea. [Product name] may cause interference in the determination of glucose and uric acid in the blood, and of metadrenaline and uric acid in urine. Pregnancy, breast-feeding and fertility Do not take this medicine if: - you are pregnant, if you may be pregnant or think you may be pregnant; - you are a woman of childbearing potential who does not use contraceptive methods. This is because this medicine may cause damage to the fetus. Do not take this medicine if you are breast-feeding. This is because the medicine passes into breast milk. This medicine may cause fertility problems in men due to potential damage to sperm (abnormal chromosome numbers). This is based on laboratory studies (see section 2 "Warnings and Precautions"). Driving and using machines There are no data regarding the effect of [Product name] on the ability to drive or use machines. Clinical studies have concluded that thiocolchicoside has no effect on psychomotor function. However, 2 there were some cases of drowsiness, which should be taken into account when driving or operating machinery. [Product name] contains sodium. This medicinal product contains less than 1 mmol (23 mg) of sodium per dose, ie it is practically "sodium-free". 3. How to take [Product name] Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is 1 to 2 tablets, 3 or 4 times a day. The duration of treatment is limited to 7 consecutive days. The tablets should be taken whole with water. Do not exceed 8 tablets / 24 hours. Do not exceed the recommended dosages and duration of treatment. This medicinal product must not be used for long-term treatment (see section 2 "Warnings and Precautions"). Use in children and adolescents Do not give this medicine to children and adolescents under 16 years of age due to safety concerns. If you take more [Product name] than you should If you accidentally take more [Product name] than you should, talk to your doctor, pharmacist or nurse. In case of overdose you may experience nausea, vomiting, anorexia, abdominal pain, diarrhea. If an overdose (more than 6 g of paracetamol in one intake, equivalent to 12 tablets in adults or more than 100 mg / kg in children) has been taken, you should go to the hospital even if there are no symptoms, as these usually begin to manifest on the third day after ingestion of the overdose. The treatment includes: Gastric lavage or induction of vomiting. Oral administration of activated charcoal; Hemodialysis; Administration of acetylcysteine in appropriate doses. If you forget to take [Product name] Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. If you stop taking [Product name] If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. Adverse effects are generally uncommon but they may be important in some cases, particularly those related to paracetamol. 3 Hepatotoxicity at high doses or prolonged treatment. Rare side effects: angioedema, allergic skin reactions, blood disorders (thrombocytopenia, pancytopenia, neutropenia, agranulocytosis and haemolytic anemia), drowsiness, nausea, vomiting, pancreatitis, fever, hypoglycaemia, jaundice, gastralgia and diarrhea. Very rare side effects: severe allergic reactions such as pruritus and urticaria. At a not known frequency, inflammation of the liver (hepatitis) and convulsions may occur (see section 2). If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine. 5. How to store [Product name] This medicine does not require any special storage conditions. Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6. Contents of the pack and other information What [Product name] contains - The active substance are paracetamol (500 mg) and thiocolchicoside (2 mg). - The other ingredients are: maize starch, hydroxypropylcellulose, sodium starch glycolate, magnesium stearate and talc. What [Product name] looks like and contents of the pack The tablets are yellowish, round, with a score line on one side. [Product name] is available in packs of 30 and 60 tablets. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder [To be completed nationally] Manufacturer Sofarimex – Indústria Química e Farmacêutica, S.A. Avenida das Indústrias, Alto do Colaride, Agualva 2735-213 Cacém 4 Portugal This medicinal product is authorised in the Member States under the following names: RMS: Portugal: Paracetamol + Tiocolquicosido Azevedos CMS: Italy: Descontran This leaflet was last revised in 10/2019 5 .
Load more

Recommended publications
  • WHO Pharmaceuticals Newsletters
    2021 WHO Pharmaceuticals No.1 NEWSLETTER The WHO Pharmaceuticals Newsletter provides you with the latest information on the safety of medicines WHO Vision for Medicines Safety and legal actions taken by regulatory authorities around No country left behind: the world. It also provides signals based on information worldwide pharmacovigilance for safer medicines, safer patients derived from the WHO global database of individual case safety reports, VigiBase. In addition, this edition of the Newsletter includes a The aim of the Newsletter is to disseminate regulatory summary of discussions and key recommendations of information on the safety of Advisory Committee on Safety of Medicinal Products pharmaceutical products, (ACSoMP) Seventeenth meeting. based on communications received from our network of national pharmacovigilance centres and other sources such as specialized bulletins and journals, as well as partners in WHO. The information is produced in the form of résumés in English, full texts of which may be obtained on request from: Safety and Vigilance: Medicines, EMP-HIS, World Health Organization, 1211 Geneva 27, Switzerland, Contents E -mail address: [email protected] This Newsletter is also available at: Regulatory matters http://www.who.int/medicines Safety of medicines Signal Feature WHO Pharmaceuticals Newsletter No. 1, 2021 ISBN 978-92-4-002136-5 (electronic version) ISBN 978-92-4-002137-2 (print version) © World Health Organization 2021 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below.
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]
  • Principios Activos Fotosensibles
    PRINCIPIOS ACTIVOS FOTOSENSIBLES PROTEGE A TUS PRODUCTOS DE LA FOTODEGRADACIÓN PRINCIPIOS ACTIVOS FOTOSENSIBLES Adenosine Carbamazepine Digitoxin Heptacaine Methaqualone-1-oxide Phenothiazines Sulfisomidine Tinidazole Vitamin D Adrenaline Carbisocaine Digoxin Hexachlorophane Methotrexate Phenylbutazone Sulpyrine Tolmetin Vitamin E Adriamycin Carboplatin Dihydroergotamin Hydralazine Metronidazole Phenylephrine Suprofen Tretinoin Vitamin K1 Amidopyrin Carmustine Dihydropyridines Mifepristone Phenytoin Triamcinolone Vitamin K2 Hydrochlorothiazide Suramin Amidinohydrazones Cefotaxime Diltiazem Hydrocortisone Minoxidil Physostigmine Triamterene Warfarin Amiloride Cefuroxime axetil Diosgenin Mitomycin C Piroxicam Tauromustine (TCNU) Trifluoperazine Hydroxychloroquine Terbutaline 4-Aminobenzoic acid Cephaeline Diphenhydramine Hypochloride Mitonafide Pralidoxime Trimethoprim Aminophenazone Cephalexine Dipyridamole Ibuprofen Mitoxantrone Prednisolone Tetracyclines Ubidecarenone Thiazide Aminophylline Cephradine Dithranol Imipramin Molsidomine Primaquine Vancomycin Thiocolchicoside Aminosalicylic acid Chalcone Dobutamin Indapamide Morphine Proguanil Vinblastine Thioridazine Amiodarone Chloramphenicol Dopamine Indomethacin Nalidixic acid Promazine Vitamin A Thiorphan Amodiaquine Chlordiazepoxide Dothiepin Indoprofen Naproxen Promethazine Vitamin B (see also Thiothixene Amonafide Chloroquine Doxorubicin Isoprenaline Neocarzinostatin Proxibarbital riboflavine) Tiaprofenic acid Amphotericin B Chlorpromazine DTIC Isopropylamino- Nimodipine Psoralen
    [Show full text]
  • Myofascial Pain Syndrome: a Treatment Review Mehul J
    Himmelfarb Health Sciences Library, The George Washington University Health Sciences Research Commons Anesthesiology and Critical Care Medicine Faculty Anesthesiology and Critical Care Medicine Publications 6-2013 Myofascial pain syndrome: A treatment review Mehul J. Desai George Washington University Vikramjeet Saini Shawnjeet Saini Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/smhs_anesth_facpubs Part of the Anesthesia and Analgesia Commons Recommended Citation Desai, M. J., Saini, V., & Saini, S. (2013). Myofascial Pain Syndrome: A Treatment Review. Pain and Therapy, 2(1), 21–36. This Journal Article is brought to you for free and open access by the Anesthesiology and Critical Care Medicine at Health Sciences Research Commons. It has been accepted for inclusion in Anesthesiology and Critical Care Medicine Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please contact [email protected]. Pain Ther (2013) 2:21–36 DOI 10.1007/s40122-013-0006-y REVIEW Myofascial Pain Syndrome: A Treatment Review Mehul J. Desai • Vikramjeet Saini • Shawnjeet Saini To view enhanced content go to www.paintherapy-open.com Received: September 27, 2012 / Published online: February 12, 2013 Ó The Author(s) 2013. This article is published with open access at Springerlink.com ABSTRACT and nonpharmacologic treatments, the authors aim to provide clinicians with a more Myofascial pain syndrome (MPS) is defined as comprehensive knowledge of the interventions pain that originates from myofascial trigger for myofascial pain. points in skeletal muscle. It is prevalent in regional musculoskeletal pain syndromes, either alone or in combination with other pain Keywords: Analgesics; Anticonvulsants; generators. The appropriate evaluation and Muscle relaxants; Myofascial pain; management of myofascial pain is an important Nonpharmacological treatment; Pain; part of musculoskeletal rehabilitation, and Treatment regional axial and limb pain syndromes.
    [Show full text]
  • Treatment for Acute Pain: an Evidence Map Technical Brief Number 33
    Technical Brief Number 33 R Treatment for Acute Pain: An Evidence Map Technical Brief Number 33 Treatment for Acute Pain: An Evidence Map Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-0000-81 Prepared by: Minnesota Evidence-based Practice Center Minneapolis, MN Investigators: Michelle Brasure, Ph.D., M.S.P.H., M.L.I.S. Victoria A. Nelson, M.Sc. Shellina Scheiner, PharmD, B.C.G.P. Mary L. Forte, Ph.D., D.C. Mary Butler, Ph.D., M.B.A. Sanket Nagarkar, D.D.S., M.P.H. Jayati Saha, Ph.D. Timothy J. Wilt, M.D., M.P.H. AHRQ Publication No. 19(20)-EHC022-EF October 2019 Key Messages Purpose of review The purpose of this evidence map is to provide a high-level overview of the current guidelines and systematic reviews on pharmacologic and nonpharmacologic treatments for acute pain. We map the evidence for several acute pain conditions including postoperative pain, dental pain, neck pain, back pain, renal colic, acute migraine, and sickle cell crisis. Improved understanding of the interventions studied for each of these acute pain conditions will provide insight on which topics are ready for comprehensive comparative effectiveness review. Key messages • Few systematic reviews provide a comprehensive rigorous assessment of all potential interventions, including nondrug interventions, to treat pain attributable to each acute pain condition. Acute pain conditions that may need a comprehensive systematic review or overview of systematic reviews include postoperative postdischarge pain, acute back pain, acute neck pain, renal colic, and acute migraine.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • THIOCOLCHICOSIDE AS MUSCLE RELAXANT: a REVIEW Introduction
    Available Online through International Journal of Pharmacy and Biological Sciences (eISSN: 2230-7605) www.ijpbs.com IJPBS |Volume 1| Issue 3 |JULY-SEPT |2011|364-371 THIOCOLCHICOSIDE AS MUSCLE RELAXANT: A REVIEW A.R Umarkar*, S.R Bavaskar & P.N.Yewale. Shree.Sureshdada Jain Institute of Pharmaceutical & Education and Research Jamner Dist: Jalgaon 424206 *Corresponding Author Email: [email protected] Review Article RECEIVED ON 29-08-2011 ACCEPTED ON 25-09-2011 ABSTRACT Thiocolchicoside, is a synthetic sulphur derivative of colchicoside, a naturally occurring glucosidecontained in the Colchicum autumnale plant Thiocolchicoside has a selective affinity for g-amino-butyric acid (GABA) receptors and acts on themuscular contracture by activating the GABA-nergicinhibitory pathways thereby acting as a potent mus-cle relaxant Thiocolchicoside (Muscoril, Myoril, Neoflax) is a muscle relaxant with anti-inflammatory and analgesic effects. It acts as a competitive GABAA receptor antagonist and also inhibits glycine receptors with similar potency and nicotinic acetylcholine receptors to a much lesser extent. It has powerful convulsant activity and should not be used in seizure- prone individuals. Mode of action includes modulation of chemokine and prostanoid production and inhibition of neutrophil and endothelial cell adhesion molecules by which it interferes with the initiation and amplification of the joint inflammation. THC is a muscle relaxant given by oral in the treatment of arthritis in a usual dose equivalent to 8 mg first day to 12-16mg /day
    [Show full text]
  • The Role of Biotransformation in Drug Discovery and Development
    b Meta olis g m & ru D T o f x o i Journal of Drug Metabolism and l c a o Kebamo et al., J Drug Metab Toxicol 2015, 6:5 n l o r g u y o J Toxicology DOI: 10.4172/2157-7609.1000196 ISSN: 2157-7609 ReviewResearch Article Article OpenOpen Access Access The Role of Biotransformation in Drug Discovery and Development Selamu Kebamo1, Shibiru Tesema2 and Bekesho Geleta3* 1Department of Pharmacology, College of Medical and Health Science, Wollega University, Ethiopia 2Deapartment of Pharmacy, College of Public Health and Medicine Science, Jimma University, Jimma, Ethiopia 3Traditional and Modern Medicine Research, Ethiopian Public Health Institute, Addis Ababa, Ethiopia Abstract Biotransformation is a process by which organic compounds are transformed from one form to another, aided by organisms such as bacteria, fungi and enzymes. It plays a major role and determines the fate of the prospective drugs. Biotransformation must take place only after the drugs reach their specific target site and produce the desired effects. In addition, the nature of the metabolites produced from the drug, must be thoroughly studied; otherwise, the drugs would be rejected during the screening process. Hence, drug metabolism is a major criterion in the high- throughput screening of prospective drugs. Biotransformation has an important role in the determination of the pharmacokinetic parameters like oral bioavailability, drug-drug interaction, clearance and the half-life of the entity within the cell. It is very essential in the toxicity studies too. Biotransformation is used as a valuable strategy to build molecules, similar to parent drug in the drug discovery programme.
    [Show full text]
  • Botulinum Toxin
    Botulinum toxin From Wikipedia, the free encyclopedia Jump to: navigation, search Botulinum toxin Clinical data Pregnancy ? cat. Legal status Rx-Only (US) Routes IM (approved),SC, intradermal, into glands Identifiers CAS number 93384-43-1 = ATC code M03AX01 PubChem CID 5485225 DrugBank DB00042 Chemical data Formula C6760H10447N1743O2010S32 Mol. mass 149.322,3223 kDa (what is this?) (verify) Bontoxilysin Identifiers EC number 3.4.24.69 Databases IntEnz IntEnz view BRENDA BRENDA entry ExPASy NiceZyme view KEGG KEGG entry MetaCyc metabolic pathway PRIAM profile PDB structures RCSB PDB PDBe PDBsum Gene Ontology AmiGO / EGO [show]Search Botulinum toxin is a protein and neurotoxin produced by the bacterium Clostridium botulinum. Botulinum toxin can cause botulism, a serious and life-threatening illness in humans and animals.[1][2] When introduced intravenously in monkeys, type A (Botox Cosmetic) of the toxin [citation exhibits an LD50 of 40–56 ng, type C1 around 32 ng, type D 3200 ng, and type E 88 ng needed]; these are some of the most potent neurotoxins known.[3] Popularly known by one of its trade names, Botox, it is used for various cosmetic and medical procedures. Botulinum can be absorbed from eyes, mucous membranes, respiratory tract or non-intact skin.[4] Contents [show] [edit] History Justinus Kerner described botulinum toxin as a "sausage poison" and "fatty poison",[5] because the bacterium that produces the toxin often caused poisoning by growing in improperly handled or prepared meat products. It was Kerner, a physician, who first conceived a possible therapeutic use of botulinum toxin and coined the name botulism (from Latin botulus meaning "sausage").
    [Show full text]
  • Management of Frozen Shoulder: a Systematic Review and Cost-Effectiveness Analysis
    Health Technology Assessment 2012; Vol. 16: No.111 Acknowledgements Health Technology Assessment 2012; Vol. 16: No. 11 ISSNContribution 1366-5278 of authors ISSN 1366-5278 ReferencesAbstractAppendix 7.2 Sodium hyaluronate Appendix 7.3 Physical therapy GlossaryAppendixAppendix 1 7.4 Acupuncture (with or without physical therapy) SearchAppendix strategies 7.5 Manipulation for effectiveness under review anaesthesia 179 ListBIOSIS ofAppendix abbreviations Previews 7.6 Distension CumulativeAppendix Index7.7 Capsular to Nursing release and Allied Health Literature (CINAHL) ExecutiveCochrane summary Central Register of Controlled Trials (CENTRAL) Clinicaltrials.govBackgroundAppendix 8 CochraneObjectivesStudy quality Database of Systematic Reviews (CDSR) 369 ConferenceMethodsControlled Proceedings trials Citation Index: Science Management of frozen shoulder: DatabaseResultsObservational of Abstracts studies of Reviews of Effects (DARE) EMBASEConclusions a systematic review and HealthFundingAppendix Management 9 Information Consortium (HMIC) HealthWinBUGS Technology code Assessment (HTA) database 373 cost-effectiveness analysis Chapter 1 Latin American and Caribbean Health Sciences Literature (LILACS) BackgroundAppendix 10 Manual, Alternative and Natural Therapy (MANTIS) TheMixed-treatment decision problem comparison 375 NHS Economic Evaluation Database (NHS EED) FrozenNetwork shoulder 1: studies of any intervention (i.e. conservative and invasive) and any quality National Technical Information Service (NTIS) DiagnosisNetwork 2:and studies management of any intervention that were of good or satisfactory quality (i.e. method E Maund, D Craig, S Suekarran, AR Neilson, PASCAL Previousof randomisation systematic was reviews adequate and outcome assessment was blinded) Physiotherapy Evidence Database (PEDro) K Wright, S Brealey, L Dennis, L Goodchild, FocusNetwork of the 3: studiessynthesis of conservative treatments of any quality PREMEDLINE Network 4: studies of conservative treatments that were of good or satisfactory quality (i.e.
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs for Acute Low Back Pain Van Der Gaag, Wendelien H; Roelofs, Pepijn Ddm; Enthoven, Wendy Tm; Van Tulder, Maurits W; Koes, Bart W
    VU Research Portal Non-steroidal anti-inflammatory drugs for acute low back pain van der Gaag, Wendelien H; Roelofs, Pepijn Ddm; Enthoven, Wendy Tm; van Tulder, Maurits W; Koes, Bart W published in The Cochrane database of systematic reviews 2020 DOI (link to publisher) 10.1002/14651858.CD013581 document version Publisher's PDF, also known as Version of record document license Article 25fa Dutch Copyright Act Link to publication in VU Research Portal citation for published version (APA) van der Gaag, W. H., Roelofs, P. D., Enthoven, W. T., van Tulder, M. W., & Koes, B. W. (2020). Non-steroidal anti-inflammatory drugs for acute low back pain. The Cochrane database of systematic reviews, 2020(4), 1-151. [CD013581]. https://doi.org/10.1002/14651858.CD013581 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. E-mail address: [email protected] Download date: 24.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]